(Bloomberg) -- Humira, the blockbuster rheumatoid arthritis treatment that generated more than $14 billion in sales last year, is likely to continue dominating the global pharmaceutical market for the next few years as AbbVie Inc. fends off challenges to its patents. Meanwhile this year’s other big drugs -- including Gilead’s Harvoni hepatitis C pill -- are likely to have a more tenuous grip on sales in the face of competing therapies and copycat medicines.
To contact the reporter on this story: Chitra Somayaji in London at email@example.com. To contact the editors responsible for this story: Chitra Somayaji at firstname.lastname@example.org, Kristen Hallam
©2016 Bloomberg L.P.